T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Background The outcome of older patients with B-cell acute lymphocytic leukaemia is
inferior to that in younger patients due to the adverse disease biology and their inability to …

Adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face
worse outcomes than children. While pediatric-inspired protocols have improved outcomes …

PURPOSE Despite recent advances in adapting the intensity of treatment for older patients
with ALL, current protocols are associated with high rates of early deaths, treatment-related …

PURPOSE We tested whether blinatumomab (Blina) is effective as a toxicity-sparing
alternative to first-line intensive chemotherapy in children and young persons (CYP) with B …

Measurable residual disease (MRD) is an adverse prognostic factor in adult patients with
acute lymphoblastic leukemia (ALL) undergoing hematopoietic cell transplant (HCT). Next …

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory
Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia …

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

While the prognostic role of immunoglobulin heavy chain locus (IGH) rearrangement in
minimal residual disease (MRD) in pediatric B-acute lymphoblastic leukemia (B-ALL) has …